AU6011096A - Chimeric leptin fused to immunoglobulin domain and use - Google Patents

Chimeric leptin fused to immunoglobulin domain and use

Info

Publication number
AU6011096A
AU6011096A AU60110/96A AU6011096A AU6011096A AU 6011096 A AU6011096 A AU 6011096A AU 60110/96 A AU60110/96 A AU 60110/96A AU 6011096 A AU6011096 A AU 6011096A AU 6011096 A AU6011096 A AU 6011096A
Authority
AU
Australia
Prior art keywords
immunoglobulin domain
leptin fused
chimeric leptin
chimeric
fused
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU60110/96A
Inventor
Michael Joseph Browne
Conrad Gerald Chapman
Helen Elizabeth Clinkenbeard
Jeffrey Hugh Robinson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Publication of AU6011096A publication Critical patent/AU6011096A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
AU60110/96A 1995-06-13 1996-06-11 Chimeric leptin fused to immunoglobulin domain and use Abandoned AU6011096A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9511935.0A GB9511935D0 (en) 1995-06-13 1995-06-13 Novel compound
GB9511935 1995-06-13
PCT/GB1996/001388 WO1997000319A2 (en) 1995-06-13 1996-06-11 Chimeric leptin fused to immunoglobulin domain and use

Publications (1)

Publication Number Publication Date
AU6011096A true AU6011096A (en) 1997-01-15

Family

ID=10775951

Family Applications (1)

Application Number Title Priority Date Filing Date
AU60110/96A Abandoned AU6011096A (en) 1995-06-13 1996-06-11 Chimeric leptin fused to immunoglobulin domain and use

Country Status (6)

Country Link
EP (1) EP0832219A2 (en)
JP (1) JPH11507547A (en)
AU (1) AU6011096A (en)
CA (1) CA2224646A1 (en)
GB (1) GB9511935D0 (en)
WO (1) WO1997000319A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU769250B2 (en) * 1995-12-27 2004-01-22 Genentech Inc. OB protein derivatives having prolonged half-life
AU770897B2 (en) * 1996-12-20 2004-03-04 Amgen, Inc. OB fusion protein compositions and methods

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6310034B1 (en) 1993-05-21 2001-10-30 Ut-Battelle, Llc Agouti polypeptide compositions
US6429290B1 (en) 1994-08-17 2002-08-06 The Rockefeller University OB polypeptides, modified forms and derivatives
US6001968A (en) * 1994-08-17 1999-12-14 The Rockefeller University OB polypeptides, modified forms and compositions
US6936439B2 (en) 1995-11-22 2005-08-30 Amgen Inc. OB fusion protein compositions and methods
US20030040467A1 (en) 1998-06-15 2003-02-27 Mary Ann Pelleymounter Ig/ob fusions and uses thereof.
CA2358862A1 (en) * 1995-11-22 1997-05-29 Amgen Inc. Methods of increasing lean tissue mass using ob protein compositions
RU2178307C2 (en) * 1995-12-27 2002-01-20 Джинентех Инк. Derivatives of protein ob
US6620413B1 (en) 1995-12-27 2003-09-16 Genentech, Inc. OB protein-polymer chimeras
US6541604B1 (en) 1996-01-08 2003-04-01 Genentech, Inc. Leptin receptor having a WSX motif
US7074397B1 (en) 1996-01-08 2006-07-11 Genentech, Inc. Method for enhancing proliferation or differentiation of a cell using ob protein
US20050019325A1 (en) 1996-01-08 2005-01-27 Carter Paul J. WSX receptor agonist antibodies
PL194159B1 (en) * 1996-12-20 2007-05-31 Amgen Inc Fusion-type protein ob - compositions and methods
CA2281888A1 (en) * 1997-02-25 1998-08-27 Eli Lilly And Company Treatment of infertility with leptin receptor ligands
ES2183351T3 (en) * 1997-04-17 2003-03-16 Amgen Inc COMPOSITIONS THAT INCLUDE CONJUGATES OF STABLE ACTIVE HUMAN PROTEIN WITH AN FC CHAIN OF IMMUNOGLOBULINS AND METHODS.
AU2002300605B8 (en) * 1997-04-17 2006-02-09 Amgen Inc. Compositions Comprising Conjugates of Stable, Active, Human OB Protein with Antibody FC Chain and Methods
US20020019352A1 (en) * 1997-04-17 2002-02-14 David N. Brems Stable, active, human ob protein compositions and methods
US6165476A (en) * 1997-07-10 2000-12-26 Beth Israel Deaconess Medical Center Fusion proteins with an immunoglobulin hinge region linker
US6187564B1 (en) 1997-07-10 2001-02-13 Beth Israel Deaconess Medical Center DNA encoding erythropoietin multimers having modified 5′ and 3′ sequences and its use to prepare EPO therapeutics
US6242570B1 (en) 1997-07-10 2001-06-05 Beth Israel Deaconess Medical Center Production and use of recombinant protein multimers with increased biological activity
WO1999002709A1 (en) * 1997-07-10 1999-01-21 Beth Israel Deaconess Medical Center Recombinant erythropoietin / immunoglobulin fusion proteins
BR9908226A (en) * 1998-02-25 2000-10-24 Lexigen Pharm Corp Improvement of the circulating half-life of fusion proteins based on antibody
CA2335107C (en) 1998-07-28 2010-01-19 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Leptin-mediated gene-induction
JP2002534962A (en) * 1999-01-07 2002-10-22 レキシジェン ファーマシューティカルズ コーポレイション Expression and transport of anti-obesity proteins as Fc fusion proteins
MXPA01011264A (en) * 1999-05-07 2002-07-02 Genentech Inc Novel chimpanzee erythropoietin (chepo) polypeptides and nucleic acids encoding the same.
WO2001025428A1 (en) * 1999-10-01 2001-04-12 Eli Lilly And Company A novel human leptin homolog
EP1252192B1 (en) * 2000-02-11 2006-08-16 MERCK PATENT GmbH Enhancing the circulating half-life of antibody-based fusion proteins
AU8178401A (en) 2000-05-22 2001-12-03 Vlaams Interuniv Inst Biotech Receptor-based interaction trap
US7235629B2 (en) 2000-11-14 2007-06-26 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Functional fragment of the leptin receptor
BR0207267A (en) * 2001-02-19 2004-02-10 Merck Patent Gmbh Artificial proteins with reduced immunogenicity
US6992174B2 (en) 2001-03-30 2006-01-31 Emd Lexigen Research Center Corp. Reducing the immunogenicity of fusion proteins
SI1641823T1 (en) 2003-06-12 2011-12-30 Lilly Co Eli Glp-1 analog fusion proteins
ES2298785T3 (en) * 2003-06-12 2008-05-16 Eli Lilly And Company FUSION PROTEINS.
CA2545539A1 (en) 2003-10-15 2005-04-28 Pdl Biopharma, Inc. Alteration of fc-fusion protein serum half-lives by mutagenesis of positions 250, 314 and/or 428 of the heavy chain constant region of ig
BRPI0406605B8 (en) 2003-11-13 2021-05-25 Hanmi Holdings Co Ltd protein conjugate, method for its preparation and pharmaceutical composition to enhance the duration and in vivo stability of a physiologically active polypeptide
US8110665B2 (en) 2003-11-13 2012-02-07 Hanmi Holdings Co., Ltd. Pharmaceutical composition comprising an immunoglobulin FC region as a carrier
EA011859B9 (en) 2004-01-05 2013-07-30 Емд Лексиген Ресерч Сентер Корп. Compounds for targeted preparation delivery to tissue or targeted organ
US7423113B2 (en) 2004-08-25 2008-09-09 Vib Vzw Leptin antagonist
EP1812038A1 (en) 2004-11-18 2007-08-01 VIB vzw Fibronectin iii domain as leptin receptor antagonists
AU2005319432A1 (en) * 2004-12-22 2006-06-29 Eli Lilly And Company GLP-1 analog fusion protein formulations
EP1976991A1 (en) * 2006-01-24 2008-10-08 Domantis Limited Fusion proteins that contain natural junctions
CA2759333A1 (en) 2009-04-22 2010-10-28 Merck Patent Gmbh Antibody fusion proteins with modified fcrn binding sites

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE169030T1 (en) * 1990-06-28 1998-08-15 Hoechst Ag FUSION PROTEINS WITH IMMUNGLOBULIN COMPONENTS, THEIR PRODUCTION AND USE
US6309853B1 (en) * 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
GB9509164D0 (en) * 1995-05-05 1995-06-28 Smithkline Beecham Plc Novel compounds
JP2000507081A (en) * 1995-05-08 2000-06-13 カイロン コーポレイション Nucleic acids for treating obesity

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU769250B2 (en) * 1995-12-27 2004-01-22 Genentech Inc. OB protein derivatives having prolonged half-life
AU770897B2 (en) * 1996-12-20 2004-03-04 Amgen, Inc. OB fusion protein compositions and methods

Also Published As

Publication number Publication date
JPH11507547A (en) 1999-07-06
WO1997000319A3 (en) 1997-04-10
WO1997000319A2 (en) 1997-01-03
CA2224646A1 (en) 1997-01-03
GB9511935D0 (en) 1995-08-09
EP0832219A2 (en) 1998-04-01

Similar Documents

Publication Publication Date Title
AU6011096A (en) Chimeric leptin fused to immunoglobulin domain and use
AU3827695A (en) Antigen-binding fusion proteins
AU3655899A (en) Modified immunoglobulin molecules and methods for use thereof
HUP9903444A3 (en) Modified/chimeric superantigens and their use
AU5155398A (en) Anti-ccr5 antibodies and methods of use therefor
AU2135795A (en) Closure
AU2466797A (en) Optical device and fusion seal
PL329404A1 (en) Chimeric isoprenoidic synthases and their application
AU4009795A (en) Heterocyclic compounds and their use
AU4266596A (en) Composition and use
HUP9900743A3 (en) Bituminous composition and using them
AU4556797A (en) Substituted phthalocyanines and their use
AU7422496A (en) NM03 antibody materials and methods
AU2077095A (en) Chromatography system and methodology
AU5452496A (en) Blends of organosilane compounds and their use
AUPN177495A0 (en) Improved closure
AU2698095A (en) Modulators of multidrug resistance transporters
AU6332396A (en) Platelet-specific chimeric immunoglobulin and methods of use therefor
AU4011495A (en) Modified cellulose-binding domain (cbd) proteins and use thereof
EP0909278A4 (en) Nephropathy-related immunoglobulin g and antibodies for same
AU1081897A (en) Heterocyclic compounds and their use
AU3634595A (en) Bis-oxazolidines and their use
AU2003200632A1 (en) MarA Family Helix-Turn-Helix Domains and their methods of use
AU5647894A (en) Chimeric human interferon-gamma-receptor/immunoglobulin polypeptides
AU7563594A (en) Chimeric receptor containing one igg binding domain of both protein a and protein g